eISSN: 2391-6052
ISSN: 2353-3854
Alergologia Polska - Polish Journal of Allergology
Current issue Archive Manuscripts accepted About the journal Supplements Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
2/2021
vol. 8
 
Share:
Send email
Share:
abstract:
Review paper

CAR-T therapy in oncology and other fields of medicine

Amelia Kierasińska
1
,
Damian Ciunowicz
2
,
Marta Węgierska
1
,
Ewelina Stoczyńska-Fidelus
2
,
Piotr Rieske
1

  1. Zakład Biologii Nowotworów, Katedra Biologii Medycznej, Uniwersytet Medyczny w Łodzi
  2. Zakład Biologii Molekularnej, Katedra Biologii Medycznej, Uniwersytet Medyczny w Łodzi
Alergologia Polska – Polish Journal of Allergology 2021; 8, 2: 77–91
DOI: https://doi.org/10.5114/pja.2021.106685
Online publish date: 2021/06/05
View full text Get citation
 
PlumX metrics:
Recently, there has been a breakthrough in immunotherapy. The development of the advanced therapy medicinal product (ATMP) is a striking example of that. Chimeric antigen receptors T cell therapy (CAR-T therapy) is the result of cooperation between biotechnologists, oncologists and immunologists. This article deals with the issues related to the development of CAR-T technology. The basics of CAR-T design and the mechanism of this therapy action are discussed. Its successes were indicated mainly in the treatment of patients with leukemias and lymphomas. EGFRvIII as an exemplary target for the therapy of solid tumors is described. However, it was pointed out what difficulties the therapy against mutated variant of epidermal growth factor receptor EGFRvIII-positive cells encounters. The growing importance of PSMA and GD2 as targets for CAR-T was also pointed out. New trends in this technology, such as the next generations of CAR-T and development of CAR-M, were noticed. Finally, the potential of CAR-T treatment in non-cancerous diseases, such as cardiac diseases, allergies or infectious diseases, including COVID-19, was characterized.
keywords:

CAR-T, leukemia, lymphoma, solid tumors, EGFRvIII, allergy, asthma, cardiac fibrosis, COVID-19, infectious diseases


Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.